Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 297 | 现货 | ||
2 mg | ¥ 433 | 现货 | ||
5 mg | ¥ 745 | 现货 | ||
10 mg | ¥ 1,160 | 现货 | ||
25 mg | ¥ 2,320 | 现货 | ||
50 mg | ¥ 3,730 | 现货 | ||
100 mg | ¥ 5,390 | 现货 | ||
500 mg | ¥ 11,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 877 | 现货 |
产品描述 | CT52923 is a selective, orally active antagonist of platelet-derived growth factor receptor (PDGFR), functioning as an ATP-competitive inhibitor. It has versatile applications for researching an array of pathological diseases such as atherosclerosis, glomerulonephritis, liver cirrhosis, pulmonary fibrosis, and cancer. |
体外活性 | CT52923 inhibits PDGFRs and stem cell factor receptors with IC50 values of 100 to 200 nM. CT52923(0.01-30 μ M; 24 h) blocks smooth muscle cell migration or fibroblast proliferation induced by platelet-derived growth factor, IC50 is 64 and 280 nM respectively [1]. |
体内活性 | CT52923 (oral; 5,15,30 and 50 mg/kg; twice daily) significantly inhibits the formation of neointima after carotid artery injury in rats [1]. |
分子量 | 467.54 |
分子式 | C23H25N5O4S |
CAS No. | 205256-55-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (128.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1389 mL | 10.6943 mL | 21.3885 mL | 53.4714 mL |
5 mM | 0.4278 mL | 2.1389 mL | 4.2777 mL | 10.6943 mL | |
10 mM | 0.2139 mL | 1.0694 mL | 2.1389 mL | 5.3471 mL | |
20 mM | 0.1069 mL | 0.5347 mL | 1.0694 mL | 2.6736 mL | |
50 mM | 0.0428 mL | 0.2139 mL | 0.4278 mL | 1.0694 mL | |
100 mM | 0.0214 mL | 0.1069 mL | 0.2139 mL | 0.5347 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CT52923 205256-55-9 Angiogenesis Tyrosine Kinase/Adaptors PDGFR CT 52923 CT-52923 Inhibitor inhibitor inhibit